Colorectal Cancer Diagnostics Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Colorectal Cancer Diagnostics Market 

5.1. COVID-19 Landscape: Colorectal Cancer Diagnostics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Colorectal Cancer Diagnostics Market, By Test Type

8.1. Colorectal Cancer Diagnostics Market, by Test Type, 2024-2033

8.1.1. Blood Test

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Stool Test

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Fecal Occult Blood Test (FOBT)

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Fecal Biomarker Test

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. CRC DNA Screening Test

8.1.5.1. Market Revenue and Forecast (2021-2033)

8.1.6. Imaging Test

8.1.6.1. Market Revenue and Forecast (2021-2033)

8.1.7. Computed Tomography (CT) scan

8.1.7.1. Market Revenue and Forecast (2021-2033)

8.1.8. Ultrasound

8.1.8.1. Market Revenue and Forecast (2021-2033)

8.1.9. Magnetic Resonance Imaging (PET) scan

8.1.9.1. Market Revenue and Forecast (2021-2033)

8.1.10. Positron Emission Tomography (PET) scan

8.1.10.1. Market Revenue and Forecast (2021-2033)

8.1.11. Colonoscopy

8.1.11.1. Market Revenue and Forecast (2021-2033)

8.1.12. Other Imaging Tests

8.1.12.1. Market Revenue and Forecast (2021-2033)

8.1.13. Biopsy

8.1.13.1. Market Revenue and Forecast (2021-2033)

8.1.14. Other Test Types

8.1.14.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Colorectal Cancer Diagnostics Market, By End-use

9.1. Colorectal Cancer Diagnostics Market, by End-use, 2024-2033

9.1.1. Hospitals

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Diagnostic Imaging Centers

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Cancer Research Centers

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Colorectal Cancer Diagnostics Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.1.2. Market Revenue and Forecast, by End-use (2021-2033)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.1.3.2. Market Revenue and Forecast, by End-use (2021-2033)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.1.4.2. Market Revenue and Forecast, by End-use (2021-2033)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.2.2. Market Revenue and Forecast, by End-use (2021-2033)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.2.3.2. Market Revenue and Forecast, by End-use (2021-2033)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.2.4.2. Market Revenue and Forecast, by End-use (2021-2033)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.2.5.2. Market Revenue and Forecast, by End-use (2021-2033)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.2.6.2. Market Revenue and Forecast, by End-use (2021-2033)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.3.2. Market Revenue and Forecast, by End-use (2021-2033)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.3.3.2. Market Revenue and Forecast, by End-use (2021-2033)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.3.4.2. Market Revenue and Forecast, by End-use (2021-2033)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.3.5.2. Market Revenue and Forecast, by End-use (2021-2033)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.3.6.2. Market Revenue and Forecast, by End-use (2021-2033)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.4.2. Market Revenue and Forecast, by End-use (2021-2033)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.4.3.2. Market Revenue and Forecast, by End-use (2021-2033)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.4.4.2. Market Revenue and Forecast, by End-use (2021-2033)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.4.5.2. Market Revenue and Forecast, by End-use (2021-2033)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.4.6.2. Market Revenue and Forecast, by End-use (2021-2033)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.5.2. Market Revenue and Forecast, by End-use (2021-2033)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.5.3.2. Market Revenue and Forecast, by End-use (2021-2033)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Test Type (2021-2033)

10.5.4.2. Market Revenue and Forecast, by End-use (2021-2033)

Chapter 11. Company Profiles

11.1. Abbott Laboratories

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. BioMerieux SA

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Dickinson and Company

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. GE Healthcare

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Qiagen N.V

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Thermo Fischer Scientific

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Hologic Inc

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Epigenomics AG

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. F-Hoffmann-La Roche Ltd

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Siemens Healthineers

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms